NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Chikungunya vaccine (live, attenuated)

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Overview

Description
A vaccine comprising live, weakened virus that protects against disease caused by chikungunya virus.
Description
A vaccine comprising live, weakened virus that protects against disease caused by chikungunya virus.
DrugBank ID
DB18701
Type
Biotech
US Approved
YES
Other Approved
NO
Patents
0
Indicated Conditions
1
Clinical Trials
Phase 0
0
Phase 1
1
Phase 2
2
Phase 3
4
Phase 4
0

Identification

Summary

Chikungunya vaccine (live, attenuated) is a live, attenuated vaccine used for the prevention of disease caused by chikungunya virus.

Brand Names
Ixchiq
Generic Name
Chikungunya vaccine (live, attenuated)
DrugBank Accession Number
DB18701
Background

Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.1 It is spread primarily by the bite of infected mosquitos of the Aedes genus. Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia.1 Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.5 There are no approved treatments for active chikungunya virus infection.4

Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease caused by chikungunya virus.3 It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Chikungunya vaccine, live
  • Chikungunya virus LR2006 OPY1 (attenuated strain) antigen
External IDs
  • VLA1553
Get Early Access To DrugBank+
Be among the first to try our new AI-powered, game-changing platform. DrugBank+ is here to streamline your pharmaceutical research and deliver faster insights and smarter decisions.
Join the Waitlist
Get Early Access To DrugBank+
Join the Waitlist

Pharmacology

Indication

Ixchiq (chikungunya vaccine, live) is indicated for the prevention of disease caused by chikungunya virus in patients ≥18 years of age who are at increased risk of exposure to chikungunya virus.2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofChikungunya virus infections•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Following intramuscular injection, viremia was not detected on day one and was detected in the greatest proportion of patients by day four.2 Viremia had resolved in all patients have day 15.2

Mechanism of action

Intramuscular injection of live chikungunya virus (CHIKV) vaccine elicits CHIKV-specific immune responses.2

Absorption

There is limited pharmacokinetic information on chikungunya virus vaccine.

Volume of distribution

There is limited pharmacokinetic information on chikungunya virus vaccine.

Protein binding

There is limited pharmacokinetic information on chikungunya virus vaccine.

Metabolism

As with other live attenuated vaccines, chikungunya virus vaccine is likely to undergo nonspecific cellular degradation.

Route of elimination

Although there is limited information on the main route of elimination of chikungunya virus vaccine, virus was detected in the urine of one participant on day 8 following intramuscular injection.2

Half-life

There is limited pharmacokinetic information on chikungunya virus vaccine.

Clearance

There is limited pharmacokinetic information on chikungunya virus vaccine.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

There are no data regarding overdosage of chikungunya virus vaccine.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirThe therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Chikungunya vaccine (live, attenuated).
Adefovir dipivoxilThe therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Adefovir dipivoxil.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Ixchiq (Valneva Austria GmbH)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
IxchiqInjection, powder, lyophilized, for solution3 [TCID_50]/0.5mLIntramuscularValneva Scotland Ltd.2024-01-15Not applicableUS flag
IxchiqPowder, for solution3 Log10 TCID50 / 0.5 mLIntramuscularValneva Sweden AbNot applicableNot applicableCanada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans
  • Chikungunya virus

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, Herrero LJ, Zaid A, Ng LFP, Mahalingam S: Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017 Apr;17(4):e107-e117. doi: 10.1016/S1473-3099(16)30385-1. Epub 2017 Feb 1. [Article]
  2. FDA Approved Drug Products: Ixchiq (Chikungunya vaccine, live) solution for intramuscular injection [Link]
  3. FDA Press Announcement: FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus [Link]
  4. Centers for Disease Control & Prevention (CDC): Chikungunya Virus [Link]
  5. Centers for Disease Control & Prevention (CDC): Areas at Risk for Chikungunya [Link]
RxNav
2673238

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
3Active Not RecruitingPreventionChikungunya Virus Infections1somestatusstop reasonjust information to hide
3CompletedPreventionChikungunya Virus Infections2somestatusstop reasonjust information to hide
3RecruitingPreventionChikungunya Virus Infections1somestatusstop reasonjust information to hide
2Active Not RecruitingPreventionChikungunya Virus Infections1somestatusstop reasonjust information to hide
1CompletedPreventionChikungunya1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular3 [TCID_50]/0.5mL
Powder, for solutionIntramuscular3 Log10 TCID50 / 0.5 mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at November 20, 2023 20:58 / Updated at August 24, 2024 11:22